Stifel Nicolaus Increases Artivion (NYSE:AORT) Price Target to $25.00

Artivion (NYSE:AORT) had its price target lifted by investment analysts at Stifel Nicolaus from $22.00 to $25.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ target price suggests a potential upside of 7.16% from the company’s previous close.

Separately, Needham & Company LLC raised their price objective on shares of Artivion from $25.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday.

Artivion Stock Down 1.9 %

Shares of NYSE AORT opened at $23.33 on Tuesday. The company has a 50 day simple moving average of $20.57 and a 200 day simple moving average of $18.18. The firm has a market cap of $961.20 million, a PE ratio of -31.11 and a beta of 1.66. Artivion has a 1 year low of $12.16 and a 1 year high of $25.51. The company has a debt-to-equity ratio of 1.10, a current ratio of 4.85 and a quick ratio of 3.43.

Artivion (NYSE:AORT) last issued its quarterly earnings data on Monday, May 6th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.04. The business had revenue of $97.43 million during the quarter, compared to analyst estimates of $92.30 million. Artivion had a negative net margin of 8.67% and a positive return on equity of 3.02%. During the same quarter last year, the business earned $0.02 EPS. On average, research analysts forecast that Artivion will post 0.26 EPS for the current year.

Insiders Place Their Bets

In other Artivion news, SVP Marshall S. Stanton sold 2,183 shares of the firm’s stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $20.39, for a total transaction of $44,511.37. Following the completion of the transaction, the senior vice president now owns 83,296 shares in the company, valued at approximately $1,698,405.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Artivion news, SVP Marshall S. Stanton sold 2,183 shares of the firm’s stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $20.39, for a total transaction of $44,511.37. Following the completion of the transaction, the senior vice president now owns 83,296 shares in the company, valued at approximately $1,698,405.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Amy Horton sold 1,695 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $18.86, for a total transaction of $31,967.70. Following the transaction, the chief accounting officer now owns 122,345 shares of the company’s stock, valued at approximately $2,307,426.70. The disclosure for this sale can be found here. In the last 90 days, insiders sold 149,952 shares of company stock worth $2,891,627. 8.10% of the stock is currently owned by insiders.

Institutional Trading of Artivion

Several hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC increased its stake in shares of Artivion by 38.6% in the 1st quarter. GAMMA Investing LLC now owns 1,814 shares of the company’s stock valued at $38,000 after acquiring an additional 505 shares in the last quarter. Texas Permanent School Fund Corp increased its stake in shares of Artivion by 2.0% in the 1st quarter. Texas Permanent School Fund Corp now owns 34,129 shares of the company’s stock valued at $722,000 after acquiring an additional 677 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Artivion by 7.8% in the 4th quarter. SG Americas Securities LLC now owns 13,393 shares of the company’s stock valued at $239,000 after acquiring an additional 968 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Artivion by 6.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 17,628 shares of the company’s stock valued at $267,000 after acquiring an additional 1,133 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Artivion by 25.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,430 shares of the company’s stock valued at $186,000 after acquiring an additional 2,108 shares in the last quarter. Institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.